Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.

Sezer, Ahmet2022-08-022022-08-0220210732-183Xhttp://hdl.handle.net/11727/7204enginfo:eu-repo/semantics/closedAccessPatient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.Conference Object391590789078000708120605058